Relay Therapeutics, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Sanjiv K. Patel
- Full Time Employees
- 202
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 60 Hampshire Street Cambridge MA United States of America 02139
- IPO Date
- Jul 16, 2020
- CIK
- 0001812364
- Website
- relaytx.com
- Similar Companies
- Business
- Relay Therapeutics, Inc. (Nasdaq: RLAY) is a clinical-stage precision medicine company that transforms drug discovery by integrating computational and experimental technologies via its proprietary Dynamo platform to target previously intractable protein motion for small-molecule therapeutics in precision oncology and genetic diseases. Founded in 2015 and headquartered in Cambridge, Massachusetts, the company advances a pipeline including RLY-2608, a pan-mutant selective PI3Kα inhibitor in Phase 3 (ReDiscover-2) for PIK3CA-mutated, HR+/HER2- metastatic breast cancer and Phase 2 (ReInspire) for PIK3CA-related vascular malformations; RLY-8161, an NRAS-selective inhibitor for NRAS-driven solid tumors advancing toward clinical development in the second half of 2025; αGal, a program for Fabry disease with clinical start planned for the second half of 2025; and lirafugratinib (RLY-4008), an FGFR2 inhibitor globally outlicensed to Elevar Therapeutics. Relay Therapeutics operates primarily in the United States with international clinical trial reach and maintains ongoing collaborations with D.E. Shaw Research for computational modeling, Pfizer for RLY-2608 combination therapies in breast cancer, and Elevar Therapeutics, which includes a late 2024 licensing deal providing up to $500 million in milestones and low-teens royalties. Recent advancements encompass disclosure of three new preclinical programs in June 2024 targeting vascular malformations, Fabry disease, and NRAS; positive Phase 3 progression-free survival data for RLY-2608; and a cash position of $596.4 million as of September 30, 2025, supporting operations into late 2026 amid cost-saving measures.
Company News
Financial Review: Relay Therapeutics (NASDAQ:RLAY) & BioMarin Pharmaceutical (NASDAQ:BMRN)
Relay Therapeutics (NASDAQ:RLAY) CEO Sells $872,401.90 in Stock
Relay Therapeutics, Inc. (RLAY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Squarepoint Ops LLC Has $1.74 Million Position in Relay Therapeutics, Inc. $RLAY
VIRGINIA RETIREMENT SYSTEMS ET Al Acquires New Stake in Relay Therapeutics, Inc. $RLAY
Relay Therapeutics, Inc. (RLAY) Presents at Wells Fargo 21st Annual Healthcare Conference Prepared Remarks Transcript
Allianz Asset Management GmbH Makes New $750,000 Investment in Relay Therapeutics, Inc. $RLAY
Frazier Life Sciences Management L.P. Takes $19 Million Position in Relay Therapeutics, Inc. $RLAY
Relay Therapeutics CFO Sells 17,717 Shares for $350,000
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September
Relay Therapeutics, Inc. $RLAY Shares Bought by Bank of America Corp DE
4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma
Relay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Lags Revenue Estimates
Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates
Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026
Relay Therapeutics, Inc. (RLAY) Expected to Beat Earnings Estimates: Should You Buy?
An AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the Numbers
Relay Therapeutics Insider Sale Tops $3 Million as Shares Surge 500% This Past Year
Relay Therapeutics, Inc. (RLAY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June